EE200200566A - Malonaamhapped ja nende derivaadid kui türoidretseptori ligandid - Google Patents

Malonaamhapped ja nende derivaadid kui türoidretseptori ligandid

Info

Publication number
EE200200566A
EE200200566A EEP200200566A EEP200200566A EE200200566A EE 200200566 A EE200200566 A EE 200200566A EE P200200566 A EEP200200566 A EE P200200566A EE P200200566 A EEP200200566 A EE P200200566A EE 200200566 A EE200200566 A EE 200200566A
Authority
EE
Estonia
Prior art keywords
derivatives
receptor ligands
thyroid receptor
malonamic acids
malonamic
Prior art date
Application number
EEP200200566A
Other languages
English (en)
Estonian (et)
Inventor
Erik Aspnes Gary
Phoebe Chiang Yuan-Ching
Gail Estep Kimberly
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200200566A publication Critical patent/EE200200566A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/80—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200200566A 2000-03-31 2001-03-07 Malonaamhapped ja nende derivaadid kui türoidretseptori ligandid EE200200566A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19361800P 2000-03-31 2000-03-31
PCT/IB2001/000317 WO2001072692A1 (en) 2000-03-31 2001-03-07 Malonamic acids and derivatives thereof as thyroid receptor ligands

Publications (1)

Publication Number Publication Date
EE200200566A true EE200200566A (et) 2004-06-15

Family

ID=22714346

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200566A EE200200566A (et) 2000-03-31 2001-03-07 Malonaamhapped ja nende derivaadid kui türoidretseptori ligandid

Country Status (38)

Country Link
US (1) US20070173548A1 (xx)
EP (1) EP1268404B1 (xx)
JP (1) JP3866977B2 (xx)
KR (1) KR20020089420A (xx)
CN (1) CN1422246A (xx)
AP (1) AP2002002634A0 (xx)
AR (1) AR033516A1 (xx)
AT (1) ATE382602T1 (xx)
AU (1) AU2001237665A1 (xx)
BG (1) BG107036A (xx)
BR (1) BR0109625A (xx)
CA (1) CA2403902C (xx)
CR (1) CR6742A (xx)
CZ (1) CZ20023190A3 (xx)
DE (1) DE60132181D1 (xx)
DZ (1) DZ3276A1 (xx)
EA (1) EA200200921A1 (xx)
EE (1) EE200200566A (xx)
GT (1) GT200100041A (xx)
HK (1) HK1052498A1 (xx)
HU (1) HUP0300329A3 (xx)
IL (1) IL151376A0 (xx)
IS (1) IS6516A (xx)
MA (1) MA26886A1 (xx)
MX (1) MXPA02009702A (xx)
NO (1) NO20024639L (xx)
NZ (1) NZ520660A (xx)
OA (1) OA12237A (xx)
PA (1) PA8513801A1 (xx)
PE (1) PE20011186A1 (xx)
PL (1) PL358596A1 (xx)
SK (1) SK13762002A3 (xx)
SV (1) SV2002000357A (xx)
TN (1) TNSN01048A1 (xx)
TR (1) TR200202249T2 (xx)
WO (1) WO2001072692A1 (xx)
YU (1) YU74102A (xx)
ZA (1) ZA200207444B (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
US6599942B1 (en) 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
MXPA02007929A (es) * 2000-02-17 2003-02-10 Squibb Bristol Myers Co Ligandos derivados de anilina para el receptor de la tiroides.
CA2433100A1 (en) * 2000-12-27 2002-07-04 Helmut Haning Indole derivatives as ligands of thyroid receptors
GB2374009A (en) * 2001-02-12 2002-10-09 Novartis Ag Method of treating hair loss
EP1499578A2 (en) 2001-08-24 2005-01-26 Karo Bio Ab Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
MX2007014502A (es) 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos para el tratamiento de enfermedades del higado graso.
GB0606201D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Improved crytalline material
WO2008017381A1 (de) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
US8633245B2 (en) * 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
JPWO2009125606A1 (ja) * 2008-04-11 2011-08-04 株式会社医薬分子設計研究所 Ｐａｉ−１阻害剤
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
AU2009309229B2 (en) 2008-10-27 2012-03-15 Cadila Healthcare Limited Thyroid receptor ligands
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010086878A2 (en) 2009-01-09 2010-08-05 Cadila Healthcare Limited Thyroid receptor modulators
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PL2695611T3 (pl) 2012-08-06 2015-03-31 Dr August Wolff Gmbh & Co Kg Arzneimittel Eprotirom do stosowania w profilaktyce i/lub leczeniu zaburzeń włosów oraz jego kompozycje
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
JP6026706B2 (ja) * 2014-04-09 2016-11-16 ゴールドクレスト医薬研究所株式会社 皮膚症状の改善剤、育毛剤又はスリミング剤
EP3541395A4 (en) 2016-11-21 2020-07-01 Viking Therapeutics, Inc. GLYCOGENOSIS TREATMENT METHODS
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
CN107474007B (zh) * 2017-08-28 2019-04-19 上海再启生物技术有限公司 一种制备3，6-二羟基苯二甲酰亚胺的方法
CN112135832A (zh) 2018-03-22 2020-12-25 维京治疗公司 化合物的晶型和制备化合物的晶型的方法
TW202115029A (zh) * 2019-07-31 2021-04-16 大陸商深圳微芯生物科技股份有限公司 雜環化合物及其用途
EP3878837A1 (en) * 2020-03-11 2021-09-15 OM Pharma SA 2,5- or 2,6-disubstituted hydroquinone derivatives with at least one carboxy, sulfo or amido group useful as medicaments

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069343A (en) * 1973-03-23 1978-01-17 American Home Products Corporation Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions
US4554290A (en) * 1983-06-17 1985-11-19 Ciba-Geigy Corporation Oxamic acid derivatives
US5061798A (en) * 1985-01-18 1991-10-29 Smith Kline & French Laboratories, Ltd. Benzyl pyridyl and pyridazinyl compounds
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5232947A (en) * 1988-07-04 1993-08-03 Meiji Seika Kaisha, Ltd. Oxamic acid compounds and pharmaceutical composition for use in improvement of damaged cerebral functions of brain
US5284971A (en) * 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
ATE159515T1 (de) * 1992-07-21 1997-11-15 Ciba Geigy Ag Oxamidsäure-derivate als hypocholesterämische mittel
CO5160290A1 (es) * 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
AU3507700A (en) * 1999-06-01 2000-12-18 University Of Texas Southwestern Medical Center, The Method of treating hair loss using diphenylether derivatives
US6664291B2 (en) * 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands

Also Published As

Publication number Publication date
CA2403902A1 (en) 2001-10-04
HK1052498A1 (zh) 2003-09-19
US20070173548A1 (en) 2007-07-26
JP2003528847A (ja) 2003-09-30
PL358596A1 (en) 2004-08-09
MA26886A1 (fr) 2004-12-20
KR20020089420A (ko) 2002-11-29
ATE382602T1 (de) 2008-01-15
IS6516A (is) 2002-08-21
DZ3276A1 (fr) 2001-10-04
MXPA02009702A (es) 2003-03-27
OA12237A (en) 2003-10-23
AR033516A1 (es) 2003-12-26
CA2403902C (en) 2007-04-24
EA200200921A1 (ru) 2003-02-27
HUP0300329A2 (hu) 2003-07-28
BG107036A (bg) 2003-04-30
AU2001237665A1 (en) 2001-10-08
NZ520660A (en) 2004-03-26
IL151376A0 (en) 2003-04-10
CZ20023190A3 (cs) 2003-10-15
YU74102A (sh) 2006-03-03
GT200100041A (es) 2002-03-22
JP3866977B2 (ja) 2007-01-10
EP1268404B1 (en) 2008-01-02
TNSN01048A1 (fr) 2005-11-10
NO20024639D0 (no) 2002-09-27
BR0109625A (pt) 2003-04-22
CN1422246A (zh) 2003-06-04
DE60132181D1 (de) 2008-02-14
SK13762002A3 (sk) 2004-01-08
WO2001072692A1 (en) 2001-10-04
TR200202249T2 (tr) 2003-01-21
PE20011186A1 (es) 2001-11-15
PA8513801A1 (es) 2002-02-21
AP2002002634A0 (en) 2002-09-30
SV2002000357A (es) 2002-07-16
HUP0300329A3 (en) 2004-08-30
CR6742A (es) 2003-11-25
EP1268404A1 (en) 2003-01-02
NO20024639L (no) 2002-09-27
ZA200207444B (en) 2003-09-17

Similar Documents

Publication Publication Date Title
EE200200566A (et) Malonaamhapped ja nende derivaadid kui türoidretseptori ligandid
EE200100464A (et) Oksaamhapped ja derivaadid kui türoidretseptori ligandid
EE200300304A (et) Bensimidasooli ja püridüülimidasooli derivaadid kui GABA-retseptorite ligandid
ATE308319T1 (de) Dosierungsform mit verlängerter wirkstoffabgabe
DE60038698D1 (de) Hydrogel-gesteuerte dosierungsform
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
DE60009963D1 (de) Wasser-in-Öl-in-Wasser Emulsion
NO20025227L (no) Tropanderivater nyttige i terapi
NO20023367D0 (no) Glyburide-preparat
EE200200150A (et) Preparaat
FI20002039A (fi) Ligandimodifioidut selluloosatuotteet
NO20032614D0 (no) Farmasöytisk sammensetning med forbedret absorbabilitet
DE60021184D1 (de) Dehnbarer vliesstoff
ATE217021T1 (de) Präparationsmittel
DE60000022D1 (de) Verbesserte teilchenförmige Zusammensetzungen
DE29907247U1 (de) Kissen
DK1019042T3 (da) Forbindelser med anti-første-passagevirkning
DE60040462D1 (de) Teilchenförmiges waschmitteladditiv
NO20030626D0 (no) Faststoff preparat med höy absorpsjonsevne
DE60006028D1 (de) Aminobutyronitril Mischung
ATA36099A (de) Stoffgemisch
DE29721135U1 (de) Hochbett mit Fallschutz
DE29810729U1 (de) Hunde-Slip
DE50010255D1 (de) Dübel
DE29713074U1 (de) Gewürzzubereitung in vorportionierter Form